Study of new drug added to ruxolitinib for myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of primary myelofibrosis, or myelofibrosis that started from essential thrombocythemia or polycythemia vera.
- You are at high, intermediate-1, or intermediate-2 risk according to a standard scoring system (IPSS).
- You have not been treated with any JAK inhibitor before.
- You have not had your spleen removed or spleen radiation in the last 3 months.
- You have not taken certain other drugs (BCL-XL, BET, MDM2, PI3K, PIM, or XPO1 inhibitors) before.
- You are not currently eligible for a bone marrow transplant, and your blood or bone marrow blasts are below 10%.
- Your myelofibrosis cells have a normal (wild-type) TP53 gene, and you are on a stable dose of ruxolitinib yet still have a suboptimal response.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This early-phase study tests whether an oral medicine called nuvisertib (TP-3654) can improve symptoms and disease control in people with myelofibrosis, including those who did not respond well to JAK inhibitors. Some participants may also receive nuvisertib with other JAK-related medicines to see which approach works best.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This study tests whether adding a type of interferon (ropeginterferon) to your current myelofibrosis treatment (ruxolitinib) is safe and tolerable. Myelofibrosis is a blood disorder where bone marrow becomes scarred; this combination might help control the disease better.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.